CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus Price Target from Analysts

Shares of CG Oncology, Inc. (NASDAQ:CGON) have earned an average rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $63.88.

CGON has been the topic of several recent analyst reports. Morgan Stanley restated an “overweight” rating and issued a $55.00 target price on shares of CG Oncology in a research note on Friday, March 7th. Royal Bank of Canada restated an “outperform” rating and issued a $66.00 target price on shares of CG Oncology in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a research note on Friday, January 10th. Finally, TD Cowen began coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock.

CG Oncology Stock Performance

Shares of NASDAQ:CGON opened at $28.03 on Friday. CG Oncology has a 52 week low of $23.91 and a 52 week high of $46.99. The company’s fifty day moving average is $28.20 and its 200-day moving average is $32.30.

Insider Activity at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Institutional Trading of CG Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in CGON. GF Fund Management CO. LTD. bought a new stake in CG Oncology during the 4th quarter worth about $41,000. Amalgamated Bank increased its stake in shares of CG Oncology by 107.6% in the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after acquiring an additional 840 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of CG Oncology in the 4th quarter valued at about $68,000. KLP Kapitalforvaltning AS bought a new stake in shares of CG Oncology in the 4th quarter valued at about $100,000. Finally, Federated Hermes Inc. bought a new stake in shares of CG Oncology in the 4th quarter valued at about $172,000. 26.56% of the stock is owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.